John Brandsema
Neurology with Special Qualifications in Child Neurology · Philadelphia, PANPI 1275889792
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Biogen at 37.3% of the total. Reporting peaked in 2019 at $168,089 and has fallen 51.4% since, to $81,614 in 2025. Among neurology with special qualifications in child neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 624 payments — averaging $842.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$196K
- Sarepta Therapeutics, Inc.$110K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$50K
- PTC Therapeutics, Inc.$44K
- Genentech USA, Inc.$38K
- Novartis$16K
- plus $73K from 15 others
Across 529 payments — averaging $7456.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$1.5M
- Biogen$910K
- Pfizer$738K
- AstraZeneca$291K
- UCB SA$86K
- ITF Therapeutics LLC$75K
- plus $298K from 8 others
What the payments were for
- Consulting fees$266,90951%
- Speaking & faculty fees$164,27331%
- Travel & lodging$77,06515%
- Food & beverage$16,5633%
- Education$7650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 284 | $196,018 |
| Sarepta Therapeutics, Inc. | 90 | $109,796 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 59 | $49,589 |
| PTC Therapeutics, Inc. | 35 | $43,576 |
| Genentech USA, Inc. | 32 | $37,934 |
| Novartis | 16 | $15,790 |
| AstraZeneca | 29 | $13,524 |
| Pfizer | 11 | $10,743 |
| ITF Therapeutics LLC | 11 | $9,797 |
| Genentech, Inc. | 12 | $9,768 |
| Argenx US, Inc. | 4 | $7,850 |
| Janssen Scientific Affairs, LLC | 10 | $6,587 |
| Janssen Research & Development, LLC | 2 | $3,750 |
| UCB SA | 1 | $2,539 |
| CSL Behring | 12 | $2,349 |
| Mesoblast, Inc. | 1 | $2,000 |
| NS Pharma, Inc. | 6 | $1,790 |
| Catalyst Pharmaceuticals, Inc. | 6 | $1,532 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $500 |
| Johnson & Johnson | 1 | $126 |
| Sanofi | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$525,575 in reported general payments places this provider in the 95th percentile of 83 neurology with special qualifications in child neurology providers in Pennsylvania.
See all neurology with special qualifications in child neurology providers in Pennsylvania →
Other neurology with special qualifications in child neurology in Philadelphia
- Susan MatesanzPhiladelphia$138K
- Elizabeth KichulaPhiladelphia$90K
- Dennis DlugosPhiladelphia$88K
- Alexandra KornbluhPhiladelphia$88K
- Nicholas AbendPhiladelphia$56K
- Sabrina YumPhiladelphia$33K
- Eric MarshPhiladelphia$28K
- Christina SzperkaPhiladelphia$18K
- David LynchPhiladelphia$16K
- Marissa DigiovinePhiladelphia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.